1-5 of 5
Michael J. Mauro
Close
Sort by
Journal Articles

Lifelong TKI therapy: how to manage cardiovascular and other risks

Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2021) 2021 (1): 113–121.
https://doi.org/10.1182/hematology.2021000239
Published: 2021
Journal Articles

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy

Mary C. Barber, Michael J. Mauro, Javid Moslehi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 110–114.
https://doi.org/10.1182/asheducation-2017.1.110
Published: 2017
Journal Articles

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

David T. Yeung, Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 240–243.
https://doi.org/10.1182/asheducation-2014.1.240
Published: 2014
Journal Articles

Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?

Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 234–239.
https://doi.org/10.1182/asheducation-2014.1.234
Published: 2014
Journal Articles

Defining and Managing Imatinib Resistance

Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 219–225.
https://doi.org/10.1182/asheducation-2006.1.219
Published: 2006